• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与已上市乙型肝炎疫苗相比，新型 HBsAg-1018 ISS 疫苗具有良好的安全性，并可增强乙型肝炎的血清保护作用。

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.

机构信息

Out-Patient Department, Philippine General Hospital, Manila, Philippines.

出版信息

Vaccine. 2012 Mar 30;30(16):2689-96. doi: 10.1016/j.vaccine.2012.02.001. Epub 2012 Feb 14.

DOI:10.1016/j.vaccine.2012.02.001
PMID:22342916
Abstract

Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B(®)). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population.

摘要

研究结果表明，40 岁及以上的成年人对目前可用的乙型肝炎病毒（HBV）疫苗的免疫反应较低。与目前已上市的乙型肝炎疫苗（安在时）相比，使用 Toll 样受体 9 激动剂 1018 免疫刺激序列（1018 ISS）佐剂联合重组乙型肝炎表面抗原（HBsAg）进行 3 次肌肉注射，可更快、更优、更持久地实现血清保护，这种免疫刺激性疫苗 HBsAg-1018ISS 的耐受性良好，其安全性与对照疫苗相似。这些结果表明，HBsAg-1018 在这种免疫反应低下的人群中可能更有效。

相似文献

1
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.与已上市乙型肝炎疫苗相比，新型 HBsAg-1018 ISS 疫苗具有良好的安全性，并可增强乙型肝炎的血清保护作用。
Vaccine. 2012 Mar 30;30(16):2689-96. doi: 10.1016/j.vaccine.2012.02.001. Epub 2012 Feb 14.
2
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.在 18-55 岁健康成年人中，比较两种剂量的研究用乙型肝炎病毒表面抗原与免疫刺激性硫代磷酸寡脱氧核苷酸联合使用，以及三种剂量的已上市乙型肝炎疫苗的安全性和免疫原性。
Vaccine. 2012 Mar 28;30(15):2556-63. doi: 10.1016/j.vaccine.2012.01.087. Epub 2012 Feb 9.
3
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.在 40-70 岁健康成年人中，与已上市乙型肝炎疫苗相比，含 Toll 样受体 9 激动剂佐剂（HBsAg-1018）的乙型肝炎疫苗的免疫原性和安全性。
Vaccine. 2013 Nov 4;31(46):5300-5. doi: 10.1016/j.vaccine.2013.05.068. Epub 2013 May 30.
4
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.在慢性肾脏病患者中，与已上市乙型肝炎疫苗相比，含 Toll 样受体 9 激动剂佐剂（HBsAg-1018）的乙型肝炎疫苗的免疫原性和安全性。
Vaccine. 2013 Nov 4;31(46):5306-13. doi: 10.1016/j.vaccine.2013.05.067. Epub 2013 May 30.
5
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.与已获许可的乙型肝炎疫苗相比，一种含Toll样受体9激动剂佐剂的研究性乙型肝炎疫苗（HBsAg-1018）在慢性肾脏病和2型糖尿病患者中的免疫原性和安全性。
Vaccine. 2015 Feb 11;33(7):833-7. doi: 10.1016/j.vaccine.2014.12.060. Epub 2015 Jan 6.
6
Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.两种剂量的研究性乙型肝炎疫苗 HBsAg-1018 与已上市乙型肝炎疫苗在成人中的免疫原性比较：使用 Toll 样受体 9 激动剂佐剂
Vaccine. 2018 Jan 29;36(5):668-674. doi: 10.1016/j.vaccine.2017.12.038. Epub 2017 Dec 27.
7
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.改良工艺乙肝疫苗在≥50岁健康成年人中的安全性和免疫原性。
Hum Vaccin. 2011 Dec;7(12):1336-42. doi: 10.4161/hv.7.12.18333. Epub 2011 Dec 1.
8
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine.在已批准的乙型肝炎疫苗无应答者中，研究性乙型肝炎疫苗（乙型肝炎表面抗原与免疫刺激性硫代磷酸寡脱氧核苷酸联合使用）的免疫原性。
Hum Vaccin Immunother. 2013 Jul;9(7):1438-44. doi: 10.4161/hv.24256. Epub 2013 Apr 9.
9
Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.一种含有Toll样受体9激动剂佐剂的研究性乙型肝炎疫苗（HBsAg-1018）与一种已获许可的乙型肝炎疫苗在18至70岁健康成人亚组中的免疫原性比较。
Vaccine. 2015 Jul 17;33(31):3614-8. doi: 10.1016/j.vaccine.2015.05.070. Epub 2015 Jun 9.
10
Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.在健康的年轻成年人中，不同两剂方案的乙型肝炎疫苗（乙型肝炎表面抗原与免疫刺激型硫代磷酸寡脱氧核苷酸联合使用）的安全性和免疫原性。
Vaccine. 2012 Aug 3;30(36):5445-8. doi: 10.1016/j.vaccine.2012.05.074. Epub 2012 Jun 13.

引用本文的文献

1
Destabilising Effect of Class B CpG Adjuvants on Different Proteins and Vaccine Candidates.B类CpG佐剂对不同蛋白质和候选疫苗的破坏作用。
Vaccines (Basel). 2025 Apr 8;13(4):395. doi: 10.3390/vaccines13040395.
2
An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination.隐匿性乙型肝炎感染（OBI）概述，重点关注乙肝疫苗接种。
Heliyon. 2024 Aug 28;10(17):e37097. doi: 10.1016/j.heliyon.2024.e37097. eCollection 2024 Sep 15.
3
Hepatitis B Vaccine: Four Decades on.乙肝疫苗：四十年回顾
Vaccines (Basel). 2024 Apr 18;12(4):439. doi: 10.3390/vaccines12040439.
4
Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.全球乙肝疫苗接种的视角：挑战、成就以及2030年实现消除的道路
Vaccines (Basel). 2024 Mar 9;12(3):288. doi: 10.3390/vaccines12030288.
5
Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand.基于脂质的重组纳米颗粒疫苗的免疫原性：危险信号与助力之手
Pharmaceutics. 2023 Dec 23;16(1):24. doi: 10.3390/pharmaceutics16010024.
6
Living with HIV and Getting Vaccinated: A Narrative Review.感染艾滋病毒后接种疫苗：一项叙述性综述。
Vaccines (Basel). 2023 Apr 25;11(5):896. doi: 10.3390/vaccines11050896.
7
Precision Vaccine Adjuvants for Older Adults: A Scoping Review.精准疫苗佐剂在老年人中的应用：综述。
Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S72-S80. doi: 10.1093/cid/ciac302.
8
Viral Hepatitis - The Road Traveled and the Journey Remaining.病毒性肝炎——走过的路与待走的旅程
Hepat Med. 2022 Mar 9;14:13-26. doi: 10.2147/HMER.S352568. eCollection 2022.
9
An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice.氢氧化铝佐剂增强了 SARS-CoV-2 受体结合域疫苗在老年小鼠中诱导的保护作用。
Sci Transl Med. 2022 Jan 26;14(629):eabj5305. doi: 10.1126/scitranslmed.abj5305.
10
Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: Double-blinded, randomised, controlled phase 2 trial.乙型肝炎病毒表面抗原免疫原性和安全性的研究：双盲、随机、对照 2 期临床试验。
Liver Int. 2021 Oct;41(10):2318-2327. doi: 10.1111/liv.14939. Epub 2021 May 24.